Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.
![](/api/deal-hero-image/109370/deal-hero-image.jpg)
![](/api/deal-party-images/109370/deal-parties.png)
Talk to the deal team
Related deals
AMC Media Group has been acquired by Formedics
AMC Media Group, a health care professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician's Weekly and OncWeekly.
Learn moreBellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Learn moreUnitary Healthcare has been acquired by Axel Health
Axel Health Oy, headquartered in Finland, has acquired the Finnish software company Unitary Healthcare Oy.
Learn more